OakChart

HUTCHMED (China) Limited ADR

HCMHealthcare·Drug Manufacturers - Specialty & Generic·Hong Kong·Mid·NASD·Nov 12 • 3:59 PM ET

14.85-0.23 (-1.53%)
2026-11-13 13:03 CET
Market cap
$2.59B
Revenue, TTM
550.48 USD m
Net income, TTM
17.92 USD m
Free cash flow, TTM
9.94 USD m
EPS diluted, TTM
0.10
Price / earnings
146.02
Compare

Price

HCM against its 20, 50 and 200-day averages
Terms2050200Earnings
Patternshover a marker to name it
RS 24Sales 300Price30032510.0012.0014.00256K512KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HCMclose 14.8520-day 14.2250-day 14.05200-day 13.1814.8552w low 9.7752-week range, not 6 months

9.1% under the 52-week high of 16.33 on 16 Jan 2026. 52-week low 9.77 on 22 Jun 2026. Last 15 sessions, 18.9% high to low

Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average

Setup. RS line 24
CANSLIM 1 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K
VCP 6 of 6
Minervini 3 of 4 — fails: Performance: Year +50%
Zanger 3 of 5 — fails: Performance: Week +10%; Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Performance: Year +50%; Average Volume: Over 500K
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 1 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years; P/E: Under 25 — not on the tape: Dividend Yield: Over 2%
Small Cap 1 of 4 — fails: Float: Under 100M; Average Volume: Over 500K; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; Average Volume: Over 500K

Profile

HCM
52-week range, 77% of the way up
9.7716.33

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Employees1796
IPOMar 17, 2016
Beta0.32
ATR, 14d0.49
Rel volume0.00
Short float0.16%
Insider own2.30%
Inst own2.53%

Snapshot

6 groups

Valuation

Index-
Market Cap$2.59B
Enterprise Value1.32B
Income17.92M
Sales550.48M
Book / share7.23
Cash / share7.88
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1796
IPOMar 17, 2016

Ratios

Price / earnings146.02
Forward price / earnings30.91
Price / earnings / growth-
Price / sales4.71
Price / book2.05
Price / cash1.88
Price / free cash flow260.65
Value / cash profit-
Value / sales2.41
Quick Ratio5.50
Current Ratio5.64
Debt / equity0.07
Long-term debt / equity0.06
Options and shortYes / Yes

Earnings

Earnings / share0.10
Earnings next year0.48
Earnings next quarter0.20
Earnings this year-85.55%
Earnings next year27.85%
Earnings growth, 5 years-
Past earnings growth- -
Past sales growth8.89% 19.22%
Earnings vs last year-96.21%
Sales vs last year-8.81%
Earnings vs last quarter-88.20%
Sales vs last quarter41.96%
EarningsJul 30 AMC
Surprise-31.03% -8.51%

Ownership

Insiders own2.30%
Insider trades0.00%
Institutions own2.53%
Institution trades1.43%
Return on assets1.02%
Return on equity1.44%
Return on capital1.34%
Gross Margin41.55%
Operating margin-6.34%
Profit Margin3.26%
20-day average4.44%
50-day average5.72%
200-day average12.69%

Technical

Shares out174.47M
Shares floating170.46M
Short / float0.16%
Short ratio3.93
Short interest0.28M
52-week high16.33 -9.1%
52-week low9.77 +52.0%
Volatility2.55% 2.65%
Average range0.49
Strength index57.63
Market sensitivity0.32
Relative volume0.00
Avg Volume70.12K
Volume0

Performance

Perf Week4.58%
Perf Month10.16%
Perf Quarter21.72%
Perf Half Y17.02%
Perf YTD11.40%
Perf Year-2.81%
Perf 3Y-21.92%
Perf 5Y-52.17%
Perf 10Y22.73%
Recommendation1.21
Target Price20.95
Prev Close14.85
Price14.85
Change %0.00%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Sep 08, 2026UpgradeHSBC SecuritiesHold → Buy
Sep 03, 2026UpgradeDaiwa SecuritiesHold → Buy
Sep 22, 2025DowngradeMorgan StanleyEqual-Weight → Underweight$13.75-7.4%
May 13, 2025DowngradeHSBC SecuritiesBuy → Hold
Nov 24, 2023UpgradeDeutsche BankHold → Buy
May 04, 2022DowngradeDeutsche BankBuy → Hold
Sep 22, 2021DowngradeGoldmanBuy → Neutral$46+209.8%
Aug 03, 2021InitiatedJefferiesBuy$52+250.2%
Oct 02, 2020InitiatedDeutsche BankBuy$40+169.4%
Mar 13, 2020InitiatedCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
ZLABZai Lab Limited ADR2.94B
EXELExelixis Inc17.04B
AAPGAscentage Pharma Group International ADR1.38B
ONCBeOne Medicines Ltd ADR43.79B
RIGLRigel Pharmaceuticals860.34M
INCYIncyte Corp24.81B
TAKTakeda Pharmaceutical Co ADR68.79B
LEGNLegend Biotech Corp ADR3.60B
AZNAstrazeneca plc285.88B
ADAGAdagene Inc ADR134.28M

Held by

AUM
TickerCompanyAUM
SPDWState Street SPDR Portfolio Developed World ex-US ETFAUM: 41.93B
DFEMDimensional Emerging Markets Core Equity 2 ETFAUM: 9.01B
DFAXDimensional World ex U.S. Core Equity 2 ETFAUM: 12.16B
DFSEDimensional Emerging Markets Sustainability Core 1 ETFAUM: 593.42M

News

latest 14 of 200
  • HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia (GlobeNewswire) +6.42%
  • HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan (GlobeNewswire)
  • HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia (GlobeNewswire)
  • Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer (GlobeNewswire)
  • HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 (GlobeNewswire)
  • HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine (GlobeNewswire)
  • HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China (GlobeNewswire)
  • HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET-Driven EGFR-Mutated Lung Cancer (GlobeNewswire)
  • HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors (GlobeNewswire)
  • HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026 (GlobeNewswire)
  • Panmure and Cavendish reiterate buy on Hutchmed after GSK deal (Proactive) +17.19%
  • HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal (Proactive)
  • HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy (GlobeNewswire)
  • HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS Plus TAGRISSO in Treatment-Naive Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China (GlobeNewswire)

Quarterly earnings

2026S1 EPS 0.100 missed 0.145. Sales 278.29 missed 304.16
EPS
2.6000-1.1552022S1 EPS -0.950 against -1.0202022S12022S2 EPS -1.1552022S22023S1 EPS 0.950 against -0.5202023S12023S2 EPS -0.400 against -0.5502023S22024S1 EPS 0.150 against -0.3932024S12024S2 EPS 0.070 against 0.0402024S22025S1 EPS 2.600 against 1.4572025S12026S1 EPS 0.100 against 0.1452026S1
Sales, USD millions
532.8702022S1 sales 202.05 against 175.222022S12022S2 sales 224.252022S22023S1 sales 532.87 against 307.932023S12023S2 sales 305.06 against 318.482023S22024S1 sales 305.7 against 319.352024S12024S2 sales 326.58 against 319.252024S22025S1 sales 277.7 against 330.42025S12026S1 sales 278.29 against 304.162026S1

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026S1ended 2026-06-302026-07-30 16:300.1000.1451.494278.29304.16EPS -31.0% · sales -8.5%-2Open +2.14% vs SPY +0.40%. Close +3.34% vs SPY +0.72%
2025S2ended 2025-12-312026-03-05 08:30-2.5000.010-307EPS - · sales --1 EPS · 2 salesOpen +0.40% vs SPY -0.45%. Close +1.50% vs SPY -0.56%
2025S1ended 2025-06-302025-08-07 16:302.6001.4572.613277.7330.4EPS +78.5% · sales -15.9%-3 EPS · 2 salesOpen -7.60% vs SPY +0.29%. Close -8.03% vs SPY +0.78%
2024S2ended 2024-12-312025-03-19 16:300.0700.0400.069326.58319.25EPS +75.0% · sales +2.3%-3 EPS · 5 salesOpen +1.61% vs SPY -0.67%. Close -0.31% vs SPY -0.29%
2024S1ended 2024-06-302024-07-31 16:300.150-0.3930.148305.7319.35EPS -138.2% · sales -4.3%-2Open -2.78% vs SPY +0.32%. Close -4.94% vs SPY -1.42%
2023S2ended 2023-12-312024-02-28 16:30-0.400-0.550-0.390305.06318.48EPS -27.3% · sales -4.2%-2Open +1.12% vs SPY +0.36%. Close -0.66% vs SPY +0.36%
2023S1ended 2023-06-302023-07-31 16:300.950-0.5200.966532.87307.93EPS -282.7% · sales +73.1%-2Open +5.19% vs SPY -0.33%. Close +7.89% vs SPY -0.29%
2022S2ended 2022-12-312023-02-28 16:30-1.155--1.139224.25-EPS - · sales --2Open +4.77% vs SPY -0.21%. Close +3.56% vs SPY -0.38%
2022S1ended 2022-06-302022-08-02-0.950-1.020-0.958202.05175.22EPS -6.9% · sales +15.3%-2Open -1.82% vs SPY -0.40%. Close -1.49% vs SPY -0.66%
2021S2ended 2021-12-312022-05-18-0.547--0.530198.89-EPS - · sales --1Open -2.19% vs SPY -1.18%. Close -15.14% vs SPY -4.03%
2021Q4ended 2021-12-312022-03-03 16:30-0.290-0.084-99.40170.6EPS +245.2% · sales -41.7%-1Open -6.24% vs SPY -0.91%. Close -11.49% vs SPY -0.81%
2021S1ended 2021-06-302021-07-29-0.700-0.895-157.36136.26EPS -21.8% · sales +15.5%-2Open +5.05% vs SPY +0.22%. Close -1.99% vs SPY +0.41%
2020S2ended 2020-12-312021-05-18-0.540--121.11-EPS - · sales --1-
2020S1ended 2020-06-302020-07-30 08:30-0.350-0.510-106.7794.06EPS -31.4% · sales +13.5%-2-
2019S2ended 2019-12-312020-03-03 08:30-0.250-0.129-53.3449.93EPS +94.6% · sales +6.8%---
2019S1ended 2019-06-302019-07-30 08:30-0.004--124.19-EPS - · sales ----

Annual earnings

2025FY EPS 2.600 missed 2.689, from 0.200 a year earlier. Sales 548.51 missed 563.75, from 630.2 a year earlier
EPS
2.6890-2.1502018FY EPS -0.565 against -0.84420182019FY EPS -0.800 against -0.93120192020FY EPS -0.900 against -0.99820202021FY EPS -1.250 against -1.64020212022FY EPS -2.150 against -2.07520222023FY EPS 0.600 against 0.05220232024FY EPS 0.200 against -0.02820242025FY EPS 2.600 against 2.6892025
Sales, USD millions
83802018FY sales 214.11 against 169.0420182019FY sales 204.89 against 195.7420192020FY sales 227.98 against 218.4720202021FY sales 356.13 against 340.6320212022FY sales 426.41 against 409.6220222023FY sales 838 against 806.420232024FY sales 630.2 against 665.8920242025FY sales 548.51 against 563.752025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate-1.170--1,18512.69
2029FYestimate-0.811--1,07318.32
2028FYestimate-0.573--798.8325.94
2027FYestimate-0.480--709.6730.91
2026FYestimate-0.376--631.4539.53
2025FY2.6002.6892.633548.51563.755.13
2024FY0.200-0.0280.216630.2665.8972.05
2023FY0.6000.0520.579838806.430.18
2022FY-2.150-2.075-2.127426.41409.62-
2021FY-1.250-1.640-1.229356.13340.63-
2020FY-0.900-0.998-0.902227.98218.47-
2019FY-0.800-0.931-0.798204.89195.74-
2018FY-0.565-0.844-5.626214.11169.04-
2017FY-0.215-0.298-2.157241.2244.17-
2016FY0.100-0.1260.998216.08211.64135.70
2015FY-0.320--3.200178.2--
2014FY0.0420.0440.05191.8182.13357.83
2013FY0.0760.0470.06645.98235.08196.17
2012FY0.066-0.0640.035195.26194225.00
2011FY0.0060.0370.006166.94172.162320.31
2010FY-0.067-0.086-134.51130.9-

Estimate revisions

Latest snapshot of each period and type. 2026FY E 0.38 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-130.38+1.3%
2026FYS-2026-11-13631.45+0.1%
2026S2Eper share2026-11-080.20-4.8%
2026S2S-2026-11-08300.4-8.7%
2026FYRper share2026-10-140.440.0%
2025FYEper share2026-03-032.70+1.9%
2025FYRper share2026-03-032.77+2.7%
2025FYS-2026-03-03563.75+2.2%
2025S2S-2026-02-28290.50.0%
2025S2Eper share2025-10-222.500.0%
2025S2Rper share2025-08-08-0.90-
2025S1S-2025-07-20330.4+0.4%
2025S1Eper share2025-07-171.46+2.6%
2024FYEper share2025-03-19-0.030.0%
2024S2Eper share2025-03-190.040.0%
2024FYRper share2025-03-19-0.090.0%
2024FYS-2025-03-19665.890.0%
2024S2S-2025-03-19317.930.0%
2024S1Eper share2024-07-24-0.39+30.8%
2024S1S-2024-07-24319.35-6.2%
2023FYEper share2024-02-240.050.0%
2023FYS-2024-02-24806.40.0%
2023FYRper share2024-02-23-0.01-58.3%
2023S2Eper share2024-02-02-0.55-1.8%
2023S2S-2024-01-22318.480.0%

Estimate history

Annual
Metric201720182019202020212022202320242025
EPS per share-2.157-5.626-0.798-0.902-1.229-2.1270.5790.2162.624
Sales USD millions242214205228357426837631550
Shares million shares1313133146173173174174174

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue550.48549.96-12.8%630.52-24.7%837.27+96.6%425.90+19.4%356.60+56.2%228.37+11.3%205.24-4.1%213.92
Cost of Goods Sold Incl. D&A321.73337.24-3.4%349.06-9.1%384.11+23.6%310.73+20.2%258.58+36.9%188.84+17.7%160.43+11.6%143.81
Gross Profit228.75212.72-24.4%281.46-37.9%453.16+293.5%115.17+17.5%98.02+148.0%39.52-11.8%44.82-36.1%70.10
Selling, General and Administrative Excl. Other263.63258.46-20.8%326.44-25.1%435.85-17.3%526.93+19.1%442.31+85.7%238.14+20.5%197.60+20.4%164.08
Research and Development155.47155.16-27.3%213.47-29.5%302.79-22.6%390.98+24.1%315.02+78.3%176.69+22.2%144.57+25.2%115.48
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-34.88-45.73-44.98-359.8%17.31-411.76-344.29-198.62-152.78-93.98
Interest Expense-2.870.0%2.87+277.6%0.76+16.9%0.65+10.2%0.59-25.3%0.79-23.3%1.03+2.0%1.01
Unusual Expense8.960.09-98.1%4.81-16.5%5.760.000.000.00--
Net Income Before Taxes16.79500.01-1.11-101.9%58.26-409.93-216.03-190.06-141.35-86.58
Income Taxes1.6663.78+785.8%7.20+59.6%4.51-0.28-102.3%11.93+146.5%4.84+47.6%3.28-17.2%3.96
Consolidated Net Income18.46458.94+1101.7%38.19-62.2%101.01-359.96-167.26-115.72-103.86-71.22
Net Income From Continuing Operations17.92458.12+1113.6%37.75-62.5%100.69-360.41-194.91-125.95-106.21-74.74
Net Income17.92458.12+1113.6%37.75-62.5%100.69-360.41-194.91-125.95-106.21-74.74
EPS (Recurring) per share0.142.62+991.7%0.24-60.0%0.60-2.13-1.23-0.90-0.80-5.63
EPS (Basic, Before Extraordinaries) per share0.102.67+1113.6%0.22-62.7%0.59-2.13-1.23-0.90-0.80-5.63
EPS (Diluted) per share0.102.62+1090.9%0.22-62.1%0.58-2.13-1.23-0.90-0.80-5.63
EBITDA-20.58-32.39-32.64-227.9%25.51-403.11-337.09-192.54-147.83-90.39
Non-Operating Income (Expense)60.63548.70+964.2%51.56+8.6%47.47+1814.1%2.48-98.1%128.85+1279.6%9.34-25.1%12.47+48.3%8.41
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.7212.11-29.1%17.08+250.0%4.88-78.7%22.91-27.3%31.53+113.6%14.76+69.5%8.71+14.8%7.59
Price To Earnings Ratio ratio statement ratio, not the snapshot146.02146.02-------
Price To Sales Ratio ratio3.414.233.993.765.8815.6019.5716.261.43
Gross Margin %41.5538.6844.6454.1227.0427.4917.3121.8432.77
Operating Margin %-6.34-8.32-7.132.07-96.68-96.55-86.97-74.44-43.93
Net Margin %3.2683.305.9912.03-84.62-54.66-55.15-51.75-34.94
Shares Outstanding million shares174.47174.47+0.1%174.32+0.0%174.25+0.7%172.96+0.0%172.91+18.8%145.54+9.1%133.38+900.6%13.33
Market Capitalization2,590.842,590.84+3.1%2,511.95-20.4%3,155.40+23.4%2,556.27-57.9%6,065.05+30.1%4,660.19+39.4%3,343.26+8.7%3,076.44

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S16/30/20262025S212/31/20252025S16/30/20252024S212/31/20242024S16/30/20242023S212/31/20232023S16/30/20232022S212/31/2022
Total Revenue278.87271.61278.36325.27305.27306.21529.63223.27
Cost of Goods Sold Incl. D&A152.47169.26167.99169.14179.89176.75207.06172.94
Gross Profit126.39102.36110.37156.13125.38129.46322.5750.33
Selling, General and Administrative Excl. Other125.52138.10113.89172.35152.86223.07211.60260.25
Research and Development78.9576.5272.17117.1295.13157.93143.75204.16
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income0.87-35.75-3.52-16.22-27.48-93.61110.97-209.92
Unusual Expense8.960.000.000.000.000.000.000.00
Net Income Before Taxes13.683.11496.813.66-4.75-79.06136.25-208.77
Income Taxes1.210.4563.324.322.881.792.713.91
Consolidated Net Income16.282.18456.6712.0326.13-68.62168.44-196.56
Net Income From Continuing Operations15.961.96456.0711.9625.77-68.01167.53-197.01
Net Income15.961.96456.0711.9625.77-68.01167.53-197.01
EPS (Recurring) per share0.130.012.610.070.15-0.390.97-1.14
EPS (Basic, Before Extraordinaries) per share0.090.012.660.070.15-0.390.99-1.14
EPS (Diluted) per share0.090.012.610.070.15-0.390.97-1.14
EBITDA7.96-28.542.61-10.12-21.24-89.20114.76-205.65
Non-Operating Income (Expense)21.7738.86500.3319.8822.7314.5525.281.15
Stock Option Compensation Expense3.934.797.328.158.922.332.5420.04
Price To Earnings Ratio ratio statement ratio, not the snapshot146.024.9769.64-29.79---
Price To Sales Ratio ratio3.414.644.353.984.893.782.766.01
Gross Margin %45.3237.6839.6548.0041.0742.2860.9122.54
Operating Margin %0.31-13.16-1.27-4.99-9.00-30.5720.95-94.02
Net Margin %5.720.72163.843.688.44-22.2131.63-88.24
Shares Outstanding million shares174.47174.47174.42174.32174.27174.25173.23172.96
Market Capitalization2,590.842,325.212,623.552,511.952,983.213,155.402,078.782,556.27

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments1,367.28+63.5%836.11-5.7%886.34+40.5%631.00-37.6%1,011.68+132.5%435.18+100.4%217.17-27.8%300.95-16.0%358.29
Short Term Receivables147.83-12.8%169.47+12.6%150.46+18.7%126.72-14.2%147.73+129.9%64.25-16.7%77.17+76.0%43.85-23.8%57.53
Inventories41.13-18.4%50.40+0.3%50.26-11.3%56.69+58.6%35.75+80.8%19.77+22.0%16.21+31.7%12.31+4.4%11.79
Other Current Assets11.11+5.1%10.57+8.0%9.79-61.6%25.48+50.9%16.89+59.0%10.62+64.1%6.47-51.8%13.43+193.2%4.58
Total Current Assets1,567.35+47.0%1,066.55-2.8%1,096.84+30.6%839.89-30.7%1,212.05+128.8%529.81+67.1%317.02-14.4%370.54-14.3%432.19
Net Property, Plant & Equipment97.65+0.7%96.99-7.1%104.39+23.3%84.67+59.3%53.15+65.1%32.19+22.1%26.37+58.7%16.62+16.9%14.22
Total Investments and Advances10.87-86.9%82.76+71.0%48.41-34.4%73.78-6.5%78.93-43.4%139.51+41.0%98.94-28.5%138.32-4.1%144.23
Long-Term Note Receivable41.38----0.00-100.0%16.19--
Intangible Assets12.05+303.0%2.99-3.2%3.09-4.0%3.22-9.0%3.54+0.3%3.53+4.1%3.39-4.0%3.53-5.6%3.74
Deferred Tax Assets12.66+1.7%12.45-19.5%15.46+0.6%15.37+63.5%9.40+518.4%1.52+87.7%0.81+39.7%0.58-7.9%0.63
Other Assets11.15-10.4%12.44+7.3%11.59-7.4%12.52-19.5%15.56-11.4%17.57+635.1%2.39-5.5%2.53-13.1%2.91
Total Assets1,753.10+37.6%1,274.19-0.4%1,279.77+24.3%1,029.45-25.0%1,372.63+89.6%724.12+55.7%465.12-12.6%532.11-11.0%597.92
Short Term Debt Incl. Current Port. of LT Debt27.85+5.9%26.30-25.0%35.08+845.6%3.71-88.3%31.82+897.5%3.19-10.9%3.58+732.6%0.43-98.9%38.10
Accounts Payable45.53+7.1%42.52+17.0%36.33-48.9%71.12+72.7%41.18+30.3%31.61+31.9%23.96-6.5%25.62+5.2%24.36
Income Tax Payable2.08+34.2%1.55-39.9%2.58+132.4%1.11-92.9%15.55+1288.4%1.12-38.8%1.83+232.7%0.55-43.9%0.98
Other Current Liabilities240.31-21.5%306.19-6.9%329.04+18.4%277.97+24.6%223.11+82.2%122.48+46.3%83.73+42.2%58.87+43.1%41.15
Total Current Liabilities315.78-16.1%376.56-6.6%403.03+13.9%353.90+13.6%311.65+96.7%158.40+40.1%113.10+32.3%85.48-18.3%104.60
Long Term Debt70.04+10.3%63.52+24.4%51.05+119.1%23.30+225.4%7.16-78.3%32.93+10.2%29.87+9.3%27.32+4610.3%0.58
Provision for Risks Charges79.960.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.26-91.3%2.99+102.0%1.48-45.4%2.71-1.8%2.76-45.5%5.06+60.1%3.16-34.7%4.84+8.8%4.45
Other Liabilities35.81-39.6%59.27-26.7%80.83+538.5%12.66+9.5%11.56+31.7%8.78+44.2%6.09+173.1%2.23-33.0%3.33
Total Liabilities501.84-0.1%502.34-6.3%536.39+36.6%392.58+17.8%333.14+62.4%205.17+34.8%152.22+27.0%119.86+6.1%112.96
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,237.93+62.9%759.93+4.0%730.54+19.7%610.37-38.2%986.87+103.8%484.12+68.1%288.01-26.0%388.99-15.8%461.73
Total Shareholders Equity1,237.93+62.9%759.93+4.0%730.54+19.7%610.37-38.2%986.87+103.8%484.12+68.1%288.01-26.0%388.99-15.8%461.73
Accumulated Minority Interest13.34+11.9%11.92-7.2%12.85-51.5%26.50-49.6%52.62+51.1%34.83+39.9%24.89+7.0%23.26+0.1%23.23
Total Equity1,251.27+62.1%771.85+3.8%743.39+16.7%636.87-38.7%1,039.49+100.3%518.95+65.9%312.90-24.1%412.25-15.0%484.96
Total Liabilities & Stockholders Equity1,753.10+37.6%1,274.19-0.4%1,279.77+24.3%1,029.45-25.0%1,372.63+89.6%724.12+55.7%465.12-12.6%532.11-11.0%597.92
Book Value Per Share per share7.10+62.8%4.36+4.1%4.19+18.7%3.53-38.2%5.71+71.5%3.33+54.2%2.16-92.6%29.18-16.0%34.74
Tangible Book Value Per Share per share7.03+62.0%4.34+4.1%4.17+18.8%3.51-38.3%5.69+72.4%3.30+54.9%2.13-92.6%28.91-16.1%34.46
Full-Time Employees people1,796-0.8%1,811-8.9%1,988-1.8%2,025+15.1%1,759+37.4%1,280+50.1%853+19.5%714+21.0%590
Price to Book Ratio ratio2.053.394.013.206.0514.8311.617.1225.29
Return on Assets %30.272.968.72-30.01-18.59-21.18-21.30-13.23-5.71
Return on Equity %45.865.0715.02-45.13-26.50-32.62-31.38-17.57-8.31
Return on Invested Capital %35.034.5812.88-56.88-19.61-24.36-33.41-17.95-5.80
Quick Ratio ratio4.832.702.602.213.773.222.664.194.02
Current Ratio ratio4.962.832.722.373.893.342.804.334.13

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income18.65458.94+1101.7%38.19-62.2%101.01-359.96-167.26-115.72-103.86-71.22
Depreciation14.3013.34+8.0%12.35+50.6%8.20-5.2%8.65+20.1%7.20+18.6%6.07+22.6%4.95+37.9%3.59
Other Funds (Non Cash)25.58-476.09-4015.2%12.16-68.6%38.78+59.0%24.39-76.93-523.9%18.15+955.2%1.72-93.8%27.66
Funds from Operations58.52-3.80-106.1%62.70-57.6%147.98-326.91-237.00-91.50-97.18-39.97
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-38.04-61.02-62.20-187.5%71.08+21.2%58.63+80.4%32.50+11.0%29.29+80.8%16.20+17.9%13.74
Cash from Operating Activities20.48-64.83-13066.0%0.50-99.8%219.07-268.28-204.49-62.21-80.99-26.23
Capital Expenditures-10.54-24.21-17.94-32.58-36.62-16.78-21.94-8.58-6.36
Net Assets From Acquisitions0.000.000.00-8.090.000.000.00-100.0%8.70-
Sale of Fixed Assets and Businesses0.030.030.00-100.0%5.100.000.000.000.00-
Purchase or Sale of Investments-14.51-5.30-79.44-255.31-176.7%332.86-275.86-103.71-187.1%119.11+137.9%50.07
Purchase of Investments-2,716.02-2,749.46-1,849.74-1,626.46-1,200.58-1,357.78-734.17-478.96-910.73
Sale Or Maturity of Investments2,701.512,744.16+55.0%1,770.29+29.1%1,371.15-10.6%1,533.44+41.7%1,081.92+71.6%630.46+5.4%598.07-37.8%960.80
Other Uses0.000.000.000.000.00-15.020.000.000.00
Other Sources0.000.00-100.0%1.280.000.00-100.0%0.930.000.000.00
Cash from Investing Activities-25.02-29.49-96.11-290.88-198.2%296.24-306.73-125.66-205.4%119.23+172.8%43.71
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.501.58-35.29-3.97-47.94-107.2%661.38+121.6%298.41-0.10-2.32
Repurchase of Common Pref Stock0.000.00-36.08-9.06-48.03-27.35-12.93-0.35-5.45
Sale of Common Pref Stock0.501.58+100.0%0.79-84.5%5.09+5555.6%0.09-100.0%688.72+121.2%311.33+124432.0%0.25-92.0%3.13
Proceedsfrom Stock Options0.501.58+100.0%0.79-84.5%5.09+5555.6%0.09-100.0%688.72+121.2%311.33+124432.0%0.25-92.0%3.13
Issuance or Reduction of Debt, Net3.396.27+11.8%5.61-90.9%61.65-9.16-0.58-1550.0%0.04-0.18-11.21
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-1.00-9.06-25.57-9.91-1.46-1.28-1.28
Other Financing Activities Uses0.000.00-1.00-9.06-25.57-9.91-1.46-1.28-1.28
Cash from Financing Activities-4.357.86-30.68-163.1%48.62-82.66-112.7%650.89+119.2%296.98-1.56-14.81
Exchange Rate Effect4.673.61-3.40-6.47-9.48-490.1%2.43-56.3%5.56-1.50-1.90
Net Change in Cash-4.22-82.85-129.70-29.66-64.19-145.2%142.10+23.9%114.67+226.0%35.18+4468.8%0.77
Free Cash Flow9.94-79.01-17.44-109.4%186.48-304.90-220.92-70.17-89.56-32.59
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow ratio189.01--16.88-----
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S16/30/20262025S212/31/20252025S16/30/20252024S212/31/20242024S16/30/20242023S212/31/20232023S16/30/20232022S212/31/2022
Cash & Short Term Investments1,374.861,367.281,364.54836.11802.47886.34856.14631.00
Short Term Receivables123.29147.83164.96169.47187.86150.46166.11126.72
Inventories40.8441.1348.4550.4046.4450.2653.8756.69
Other Current Assets14.4611.1114.4010.5711.519.7914.3325.48
Total Current Assets1,553.461,567.351,592.351,066.551,048.291,096.841,090.45839.89
Net Property, Plant & Equipment93.7997.6594.5796.9994.82104.3996.8384.67
Total Investments and Advances11.0210.878.6582.7680.5248.4137.7473.78
Intangible Assets-12.05-2.99-3.09-3.22
Deferred Tax Assets-12.66-12.45-15.46-15.37
Other Assets34.1911.1540.6212.4437.2711.5939.5512.52
Total Assets1,736.481,753.101,775.971,274.191,260.901,279.771,297.461,029.45
Short Term Debt Incl. Current Port. of LT Debt22.4127.8525.6026.3026.4735.080.003.71
Accounts Payable33.6545.5343.7342.5243.4036.3354.5771.12
Income Tax Payable-2.08-1.55-2.58-1.11
Other Current Liabilities219.17240.31273.03306.19303.43329.04286.28277.97
Total Current Liabilities275.22315.78342.35376.56373.30403.03340.85353.90
Long Term Debt72.1070.0470.9563.5255.6351.0540.1523.30
Deferred Tax Liabilities-0.26-2.99-1.48-2.71
Other Liabilities30.5435.8144.7459.2779.9380.83116.4712.66
Total Liabilities461.47501.84534.03502.34508.86536.39497.46392.58
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity1,260.821,237.931,229.09759.93740.10730.54782.01610.37
Total Shareholders Equity1,260.821,237.931,229.09759.93740.10730.54782.01610.37
Accumulated Minority Interest14.1913.3412.8611.9211.9312.8517.9826.50
Total Equity1,275.011,251.271,241.94771.85752.04743.39799.99636.87
Total Liabilities & Stockholders Equity1,736.481,753.101,775.971,274.191,260.901,279.771,297.461,029.45
Book Value Per Share per share7.237.107.054.364.254.194.513.53
Tangible Book Value Per Share per share7.237.037.054.344.254.174.513.51
Price to Book Ratio ratio2.051.893.453.394.084.012.663.20
Return on Assets %1.0230.2630.822.95-3.308.62-2.37-
Return on Equity %1.4445.8547.545.06-5.5514.84-3.73-
Return on Invested Capital %1.200.1535.081.453.24-8.7020.38-31.09
Quick Ratio ratio5.504.834.512.702.682.603.042.21
Current Ratio ratio5.644.964.652.832.812.723.202.37

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026S16/30/20262025S212/31/20252025S16/30/20252024S212/31/20242024S16/30/20242023S212/31/20232023S16/30/20232022S212/31/2022
Net Income16.282.37456.6712.1326.13-66.98168.44-195.98
Depreciation7.097.216.136.136.244.453.794.25
Other Funds (Non Cash)18.846.73-482.9333.94-21.7622.7016.2513.46
Funds from Operations42.2116.32-20.1252.1910.62-39.84188.48-178.27
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-29.96-8.09-52.95-11.92-50.4011.1460.260.72
Cash from Operating Activities12.258.23-73.0740.28-39.78-28.70248.74-177.56
Capital Expenditures-5.64-4.90-19.31-7.88-10.09-8.52-24.21-20.75
Net Assets From Acquisitions0.000.000.000.000.00-8.120.000.00
Sale of Fixed Assets and Businesses0.010.020.010.000.005.120.000.00
Purchase or Sale of Investments27.74-42.2536.94-83.834.2457.09-313.5356.54
Purchase of Investments-1,270.90-1,445.12-1,304.97-863.36-989.72-803.65-830.01-618.34
Sale Or Maturity of Investments1,298.641,402.871,341.91779.53993.96860.74516.48674.88
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.860.430.000.000.00
Cash from Investing Activities22.11-47.1317.64-90.85-5.4345.57-337.7535.78
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.020.481.100.43-35.793.97-7.960.31
Repurchase of Common Pref Stock0.000.000.00-0.13-36.02-0.09-9.020.17
Sale of Common Pref Stock0.020.481.100.560.234.061.050.14
Proceedsfrom Stock Options0.020.481.100.560.234.061.050.14
Issuance or Reduction of Debt, Net-2.88-1.978.241.354.2739.1522.7717.34
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.00-1.00-0.09-9.01-25.48
Other Financing Activities Uses0.000.000.00-0.00-1.00-0.09-9.01-25.48
Cash from Financing Activities-2.86-1.499.341.78-32.5243.045.79-7.82
Exchange Rate Effect3.810.872.75-1.60-1.800.02-6.52-4.20
Net Change in Cash35.30-39.52-43.35-50.40-79.5359.94-89.73-153.79
Free Cash Flow6.613.33-82.3632.40-49.87-37.22224.53-198.31
Price to Free Cash Flow ratio189.01----16.8579.37-

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Collaboration Research And Development57.9727.90-51.9%5.1%
Commercialization Services52.4945.30-13.7%8.3%
Goods Distribution266.84262.97-1.4%47.9%
License And Collaborations Manufacturing supply10.3931.19+200.1%5.7%
Marketed Products128.01100.64-21.4%18.3%
Other Collaboration Licensing43.0012.09-71.9%2.2%
Other Collaboration Royalties71.0468.42-3.7%12.5%
Research And Development Services0.47---
Total630.20548.51-13.0%100.0%
Region
Name20242025vs 20242025 share
China452.41407.45-9.9%74.3%
United States And Others177.79141.06-20.7%25.7%
Total630.20548.51-13.0%100.0%
Segment
Name20242025vs 20242025 share
Oncology Or Immunology363.37285.54-21.4%52.1%
Other Ventures266.84262.97-1.4%47.9%
Total630.20548.51-13.0%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.16%0.3M170.5M66.51K
2026-10-150.16%0.3M170.5M68.72K
2026-09-300.16%0.3M170.5M68.85K
2026-09-150.13%0.2M170.5M67.83K
2026-08-310.12%0.2M170.5M59.26K
2026-08-140.10%0.2M170.5M52.33K
2026-07-310.11%0.2M170.5M51.28K
2026-07-150.11%0.2M170.5M48.01K
2026-06-300.12%0.2M170.5M44.11K
2026-06-150.12%0.2M170.5M41.97K
2026-05-290.12%0.2M170.5M33.87K
2026-05-150.13%0.2M170.5M29.67K
2026-04-300.15%0.3M170.5M29.85K
2026-04-150.18%0.3M170.5M30.46K
2026-03-310.16%0.3M170.5M37.38K
2026-03-130.16%0.3M170.5M36.83K
2026-02-270.19%0.3M170.5M34.47K
2026-02-130.18%0.3M170.5M36.87K
2026-01-300.19%0.3M170.5M38.05K
2026-01-150.20%0.3M170.5M37.58K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5010.0014.900.0036.8800.000.000.992-0.0190.000
call5.007.5012.300.0013.5700.000.000.935-0.1440.003
call7.505.009.805.529.1141.000.000.894-0.1400.004
call10.002.557.403.576.6212.000.000.841-0.1270.005
call12.500.504.902.424.59915.000.000.751-0.1030.007
call15.000.002.001.155.24517.000.000.607-0.1720.009
call17.500.004.900.003.2590.000.000.468-0.1790.009
call20.000.004.900.003.9620.000.000.422-0.2140.009
call22.500.004.900.004.5190.000.000.394-0.2390.009
call25.000.004.900.004.9820.000.000.374-0.2600.008
call30.000.004.900.005.7240.000.000.349-0.2910.008
put2.500.000.050.005.9280.000.00-0.008-0.0170.001
put5.000.004.900.008.0190.000.00-0.065-0.1390.003
put7.500.004.900.005.4540.000.00-0.104-0.1360.004
put10.000.004.900.853.7466.000.00-0.159-0.1260.005
put12.500.000.900.403.07432.000.00-0.263-0.1330.008
put15.000.103.501.003.99215.000.00-0.418-0.1680.008
put17.500.004.900.003.7220.000.00-0.531-0.1800.009
put20.002.657.500.004.5070.000.00-0.579-0.2200.009
put22.505.1010.000.005.0800.000.00-0.606-0.2460.008
put25.007.6012.500.005.5570.000.00-0.626-0.2670.008
put30.0012.6017.500.006.3240.000.00-0.651-0.2980.008

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-05SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-26SEC
2026-10-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-21SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-28SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-03SEC
2026-08-316-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-31SEC
2026-08-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-28SEC
2026-08-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-18SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC
2026-06-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-06-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-29SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-25SEC
2026-06-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-06-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-05SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-21SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-20SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-12SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SCHRODER INVESTMENT MANAGEMENT GROUP0.85%
Allianz Asset Management GmbH0.39%
STATE STREET CORP0.18%
AIA Group Ltd0.15%
M&G Plc0.14%
JANE STREET GROUP, LLC0.13%
Amundi0.08%
RENAISSANCE TECHNOLOGIES LLC0.07%
Crossmark Global Holdings, Inc.0.06%
XY Capital Ltd0.06%

Funds

Fund% owned
Steward Values Enhanced International Fund0.05%
State Street(R) SPDR(R) Portfolio Developed World ex-US ETF0.04%
Tema Oncology ETF0.04%
Fidelity Nasdaq Composite Index Fund0.01%
National Security Emerging Markets Index ETF0.00%
Dimensional Emerging Markets Core Equity 2 ETF0.00%
THE EMERGING MARKETS SMALL CAP SERIES0.00%
World ex U.S. Core Equity Portfolio0.00%
Dimensional World ex. U.S. Core Equity 2 ETF0.00%
EMERGING MARKETS CORE EQUITY 2 PORTFOLIO0.00%

OakChart. HCM. Cached 15 minutes. Terms

Some panels did not load: insider.